Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SABS | 8-K | bullish | 6/10 | SAB Biotherapeutics announced FDA Fast Track designation for SAB-142, its disease-modifying immunotherapy for Stage 3 ty | Oct 13, 2026 |
| MTVA | 8-K | neutral | 3/10 | MetaVia Inc. appointed Sarah Kaplan Browne, M.D. as Chief Medical Officer, effective October 12, 2026. Dr. Browne brings | Oct 13, 2026 |
| TRAX | 8-K | bullish | 7/10 | First Tracks Biotherapeutics announced positive top-line results from Cohort 1 of ANB033's Phase 1b gluten-challenge tri | Oct 13, 2026 |
| SABS | PRESS-RELEASE | bullish | 5/10 | SAB Biotherapeutics announced FDA Fast Track designation for its lead candidate SAB-142, a disease-modifying immunothera | Oct 13, 2026 |
| IBIO | 8-K | bullish | 5/10 | iBio released preclinical body-composition data from an obese NHP study of IBIO-610, a first-in-class Activin E antibody | Oct 13, 2026 |
| JNJ | 8-K | mixed | 6/10 | JNJ reported Q3 2026 adjusted EPS of $2.59, a -11.2% miss vs consensus of $2.92, and revenue of $25.4B vs $26.43B consen | Oct 13, 2026 |
| ONCY | 8-K | neutral | 3/10 | Oncolytics Biotech filed an 8-K announcing updates to its intellectual property portfolio for pelareorep. A new method-o | Oct 13, 2026 |
| MIRM | 8-K | bullish | 7/10 | Mirum Pharmaceuticals announced positive topline results from the Phase 3 EXPAND study of LIVMARLI (maralixibat) in ultr | Oct 13, 2026 |
| SCNX | PRESS-RELEASE | bearish | 5/10 | Scienture Holdings reported preliminary Q3 2026 revenue of ~$1.22M, a 256% sequential increase from Q2 2026's $344K, dri | Oct 13, 2026 |
| GALT | DEFA14A | neutral | 5/10 | Galectin Therapeutics filed DEFA14A definitive additional proxy soliciting materials on October 13, 2026, in connection | Oct 13, 2026 |
| IMRN | 6-K | neutral | 3/10 | Immuron announced the publication of its Phase 2 clinical trial data for once-daily oral Travelan in the journal Scienti | Oct 13, 2026 |
| GALT | DEF 14A | bearish | 6/10 | Galectin Therapeutics filed its definitive proxy statement for the 2026 annual meeting, seeking shareholder approval to | Oct 13, 2026 |
| CDT | 8-K | bearish | 7/10 | CDT Equity Inc. issued a $6,750,000 senior secured convertible note to J.J. Astor & Co., receiving $3,000,000 in the fir | Oct 13, 2026 |
| HRMY | 8-K | neutral | 3/10 | Harmony Biosciences announced a planned CEO transition: current CEO Jeffrey Dayno will retire on December 31, 2026, and | Oct 13, 2026 |
| SCNI | 6-K | bullish | 6/10 | Scinai Immunotherapeutics announced a $5.1 million definitive development and clinical manufacturing CDMO agreement with | Oct 13, 2026 |
| GMAB | 6-K | neutral | 4/10 | Genmab reported Q3 2026 worldwide net trade sales of DARZALEX (daratumumab) of USD 4,239 million, with USD 2,528 million | Oct 13, 2026 |
| ADIA | 8-K | neutral | 3/10 | Adia Med, Inc. fully repaid and discharged a $1,000,000 unsecured revolving line of credit from its CEO, Larry Powalisz, | Oct 13, 2026 |
| ZTS | 8-K | neutral | 2/10 | Zoetis appointed Iris Knobloch to its Board of Directors, effective December 1, 2026, increasing board size from 12 to 1 | Oct 13, 2026 |
| LEGN | 6-K | bullish | 6/10 | Legend Biotech announced preliminary Q3 2026 net trade sales of approximately $710 million for CARVYKTI, its only approv | Oct 13, 2026 |
| NBP | 6-K | bullish | 5/10 | NovaBridge's majority-owned ophthalmology subsidiary Visara in-licensed VIS-102 (HT006.2.2), a modified recombinant huma | Oct 13, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK filed a Form 6-K reporting routine share acquisitions by multiple PDMRs (including the CEO, CFO, and other senior ex | Oct 13, 2026 |
| MESO | 6-K | mixed | 6/10 | Mesoblast filed its FY2026 annual report (20-F) via a 6-K, reporting first full-year product revenue of $115.2M from Ryo | Oct 13, 2026 |
| ADCT | 8-K | bullish | 7/10 | ADC Therapeutics announced a comprehensive capital restructuring: an $86.6M PIPE (12.9M shares at $1.42 + 48.1M pre-fund | Oct 13, 2026 |
| NRIX | 8-K | bullish | 7/10 | Nurix Therapeutics reported Q3 2026 revenue of $673.1M (vs $7.9M YoY) and net income of $549.8M ($4.73 diluted EPS), mas | Oct 13, 2026 |
| PULM | 425 | neutral | 4/10 | Pulmatrix filed a 425 communication highlighting preclinical data for Eos SENOLYTIX's lead candidate PTC-2105, showing a | Oct 13, 2026 |
| CMND | 6-K | neutral | 3/10 | Clearmind Medicine's 51%-owned subsidiary Charging Robotics launched a next-generation automated EV-charging platform fo | Oct 13, 2026 |
| NVO | 6-K | neutral | 2/10 | Novo Nordisk filed a routine 6-K disclosing weekly B-share repurchases under its existing DKK 15 billion buyback program | Oct 13, 2026 |
| GDTC | SC 13D/A | neutral | 3/10 | Chairman Choo Chee Kong filed an amended Schedule 13D disclosing open-market purchases of 62,000 ordinary shares of Cyto | Oct 13, 2026 |
| TENX | SC 13G/A | bullish | 5/10 | Sphera Funds Management Ltd. and related entities filed an amended Schedule 13G disclosing a 7.09% passive beneficial ow | Oct 13, 2026 |
| AVBP | 8-K | neutral | 4/10 | ArriVent BioPharma dosed the first patient in a Phase 1 U.S. trial for ARR-002, a novel first-in-class MUC16/NaPi2b dual | Oct 13, 2026 |